Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News vTv Therapeutics Inc VTVT

Healthcare Biotechnology
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of... see more

Recent & Breaking News (NDAQ:VTVT)

vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update

GlobeNewswire October 30, 2019

vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin

GlobeNewswire October 3, 2019

vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes

GlobeNewswire September 18, 2019

vTv Therapeutics to Present Posters at Two Scientific Conferences in September

GlobeNewswire September 11, 2019

vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

GlobeNewswire September 4, 2019

vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences

GlobeNewswire August 6, 2019

vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update

GlobeNewswire July 31, 2019

vTv Therapeutics to Present at 2019 Alzheimer's Association International Conference

Business Wire July 15, 2019

vTv Therapeutics Initiates Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

Business Wire June 27, 2019

vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes

Business Wire June 6, 2019

vTv Therapeutics Announces 2019 First Quarter Financial Results and Update

Business Wire May 1, 2019

vTv Therapeutics to Present at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases

Business Wire March 28, 2019

vTv Therapeutics Announces $15 Million of Class A Common Stock Financings

Business Wire March 18, 2019

vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update

Business Wire February 27, 2019

vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study

Business Wire January 16, 2019

16 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  January 2, 2019

Mid-Afternoon Market Update: Dow Up 175 Points; Pulmatrix Shares Plunge

Benzinga.com  December 31, 2018

Mid-Day Market Update: Bridgeline Digital Drops After Q4 Results; Safe-T Group Shares Jump

Benzinga.com  December 31, 2018

Thinking about buying stock in Aurinia Pharmaceuticals Inc, Eagle Bancorp, Canada Goose Holdings Inc., New Age Beverages Corp, or vTv Therapeutics Inc.?

PR Newswire December 31, 2018

Mid-Afternoon Market Update: Dow Rises 150 Points; Obalon Therapeutics Shares Plunge

Benzinga.com  December 28, 2018